PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
July 2, 2026Drugs & Therapy Perspectives

Consider frailty status and comorbidities when choosing anticoagulant treatment for older patients with atrial fibrillation

View Full Paper
Ask AI
Bookmark
Share

Why the study?

How should frailty and comorbidities influence the choice between DOACs and warfarin in older patients with atrial fibrillation?

Population

Older patients with atrial fibrillation, including those with advanced age, frailty, increased risk of…

Comparison

Direct oral anticoagulants (DOACs) vs Warfarin (vitamin K antagonist)

Design

Review

Key result

Direct oral anticoagulants likely offer greater treatment benefits than warfarin for older patients with atrial fibrillation, though individualized approaches are needed for frail patients.

Authors

AMAisling McGuigan

Discussion

Loading...

Member takes

Overview

Supports individualized DOAC use in older AF patients; leaves open frailty-specific prospective trials.

Key Points

  • To assess the effectiveness of anticoagulants in older patients with atrial fibrillation, considering frailty and comorbidities.
  • Evaluated the use of direct oral anticoagulants (DOACs) vs warfarin in older patients with atrial fibrillation.
  • Considered patient factors like frailty, chronic kidney disease, and history of bleeding when determining treatment options.
  • DOACs show greater treatment benefits compared to warfarin in older patients with atrial fibrillation.
  • Patient subgroups with frailty and comorbidities still retain benefits from DOACs despite increased bleeding risks.

Structured PICO

How should frailty and comorbidities influence the choice between DOACs and warfarin in older patients with atrial fibrillation?

P
Population
Older patients with atrial fibrillation, including those with advanced age, frailty, increased risk of falling, chronic kidney disease, or a history of bleeding
I
Intervention
Direct oral anticoagulants (DOACs)
C
Comparator
Warfarin (vitamin K antagonist)
O
Outcome
Risk of stroke and major bleeding

DOACs are generally preferred over warfarin in older patients with AF, but individualized assessment is crucial for those with frailty or significant comorbidities.

Cite This Study

Aisling McGuigan (2026) conducted a review in Atrial fibrillation. Direct oral anticoagulants (DOACs) vs. Warfarin was evaluated. Direct oral anticoagulants likely offer greater treatment benefits than warfarin for older patients with atrial fibrillation, though individualized approaches are needed for frail patients.

synapsesocial.com/papers/6a4602ec9ed1343031311b72https://doi.org/10.1007/s40267-026-01248-7
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Direct oral anticoagulants in older patients with atrial fibrillation and comorbidities: frailty, renal impairment, acute or chronic coronary syndromes, and acute stroke2026
  2. 2Clinical Outcomes of Oral Anticoagulation in Elderly East Asian Patients with Atrial Fibrillation: A Retrospective Single-Center Study2025
  3. 3How can we reduce thrombotic and hemorrhagic events in elderly patients with atrial fibrillation?2025 · 3 citations
  4. 4The prevalence and burden of chronic kidney disease, patterns of anticoagulation prescribing, and major bleeding risk in older adults with atrial fibrillation2025
  5. 5Anticoagulation in Atrial Fibrillation and Dementia2025